Literature DB >> 20154587

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Robert J Kurman1, Ie-Ming Shih.   

Abstract

Ovarian cancer is the most lethal gynecologic malignancy. Efforts at early detection and new therapeutic approaches to reduce mortality have been largely unsuccessful, because the origin and pathogenesis of epithelial ovarian cancer are poorly understood. Despite numerous studies that have carefully scrutinized the ovaries for precursor lesions, none have been found. This has led to the proposal that ovarian cancer develops de novo. Studies have shown that epithelial ovarian cancer is not a single disease but is composed of a diverse group of tumors that can be classified based on distinctive morphologic and molecular genetic features. One group of tumors, designated type I, is composed of low-grade serous, low-grade endometrioid, clear cell, mucinous and transitional (Brenner) carcinomas. These tumors generally behave in an indolent fashion, are confined to the ovary at presentation and, as a group, are relatively genetically stable. They lack mutations of TP53, but each histologic type exhibits a distinctive molecular genetic profile. Moreover, the carcinomas exhibit a shared lineage with the corresponding benign cystic neoplasm, often through an intermediate (borderline tumor) step, supporting the morphologic continuum of tumor progression. In contrast, another group of tumors, designated type II, is highly aggressive, evolves rapidly and almost always presents in advanced stage. Type II tumors include conventional high-grade serous carcinoma, undifferentiated carcinoma, and malignant mixed mesodermal tumors (carcinosarcoma). They displayTP53 mutations in over 80% of cases and rarely harbor the mutations that are found in the type I tumors. Recent studies have also provided cogent evidence that what have been traditionally thought to be primary ovarian tumors actually originate in other pelvic organs and involve the ovary secondarily. Thus, it has been proposed that serous tumors arise from the implantation of epithelium (benign or malignant) from the fallopian tube. Endometrioid and clear cell tumors have been associated with endometriosis that is regarded as the precursor of these tumors. As it is generally accepted that endometriosis develops from endometrial tissue by retrograde menstruation, it is reasonable to assume that the endometrium is the source of these ovarian neoplasms. Finally, preliminary data suggest that mucinous and transitional (Brenner) tumors arise from transitional-type epithelial nests at the tubal-mesothelial junction by a process of metaplasia. Appreciation of these new concepts will allow for a more rationale approach to screening, treatment, and prevention that potentially can have a significant impact on reducing the mortality of this devastating disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154587      PMCID: PMC2841791          DOI: 10.1097/PAS.0b013e3181cf3d79

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  44 in total

1.  Tubal ligation and risk of ovarian cancer.

Authors:  J M Piek; P J van Diest; R P Zweemer; P Kenemans; R H Verheijen
Journal:  Lancet       Date:  2001-09-08       Impact factor: 79.321

Review 2.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

3.  Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation.

Authors:  D T Wheeler; K A Bell; R J Kurman; M E Sherman
Journal:  Am J Surg Pathol       Date:  2000-06       Impact factor: 6.394

4.  Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations.

Authors:  L Deligdisch; J Gil; H Kerner; H S Wu; D Beck; R Gershoni-Baruch
Journal:  Cancer       Date:  1999-10-15       Impact factor: 6.860

Review 5.  Precursors to pelvic serous carcinoma and their clinical implications.

Authors:  Ann K Folkins; Elke A Jarboe; Michael H Roh; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2009-02-23       Impact factor: 5.482

6.  Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.

Authors:  Kuan-Ting Kuo; Bin Guan; Yuanjian Feng; Tsui-Lien Mao; Xu Chen; Natini Jinawath; Yue Wang; Robert J Kurman; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

7.  Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.

Authors:  P J Paley; E M Swisher; R L Garcia; S N Agoff; B E Greer; K L Peters; B A Goff
Journal:  Gynecol Oncol       Date:  2001-02       Impact factor: 5.482

8.  Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.

Authors:  Emanuela Veras; Tsui-Lien Mao; Ayse Ayhan; Stefanie Ueda; Hong Lai; Mutlu Hayran; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2009-06       Impact factor: 6.394

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.

Authors:  Patricia A Shaw; Marjan Rouzbahman; Ellen S Pizer; Melania Pintilie; Heather Begley
Journal:  Mod Pathol       Date:  2009-06-19       Impact factor: 7.842

View more
  548 in total

1.  Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.

Authors:  Yuji Matsuo; Hironori Tashiro; Hiroyuki Yanai; Takuya Moriya; Hidetaka Katabuchi
Journal:  Med Mol Morphol       Date:  2014-11-15       Impact factor: 2.309

2.  Establishment of a New Ovarian Cancer Cell Line CA5171.

Authors:  Ying-Cheng Chiang; Wen-Fang Cheng; Ming-Cheng Chang; Tzu-Pin Lu; Kuan-Ting Kuo; Hsiu-Ping Lin; Chang-Yao Hsieh; Chi-An Chen
Journal:  Reprod Sci       Date:  2014-11-12       Impact factor: 3.060

3.  ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.

Authors:  Hua Li; Benjamin G Bitler; Vinod Vathipadiekal; Marie E Maradeo; Michael Slifker; Caretha L Creasy; Peter J Tummino; Paul Cairns; Michael J Birrer; Rugang Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-05

Review 4.  Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting.

Authors:  Antonio González-Martín; Gemma Toledo; Luis Chiva
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

5.  Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.

Authors:  Rajesh Singh; Cecil R Stockard; William E Grizzle; James W Lillard; Shailesh Singh
Journal:  Int J Oncol       Date:  2011-05-31       Impact factor: 5.650

6.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

7.  Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis.

Authors:  Elisabetta Kuhn; Alan Meeker; Tian-Li Wang; Ann Smith Sehdev; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-06       Impact factor: 6.394

Review 8.  The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.

Authors:  Xiyin Wang; Mircea Ivan; Shannon M Hawkins
Journal:  Gynecol Oncol       Date:  2017-08-31       Impact factor: 5.482

9.  Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.

Authors:  Dirk Bauerschlag; Karen Bräutigam; Roland Moll; Jalid Sehouli; Alexander Mustea; Darius Salehin; Maryla Krajewska; John C Reed; Nicolai Maass; Garret M Hampton; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-23       Impact factor: 4.553

Review 10.  Origin of ovarian cancer: molecular profiling.

Authors:  Dilip Kumar Dutta; Indranil Dutta
Journal:  J Obstet Gynaecol India       Date:  2013-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.